EP0002259A2 — Hydantoin derivatives and salts thereof, their synthesis and pharmaceutical formulations
Assigned to Wellcome Foundation Ltd · Expires 1979-06-13 · 47y expired
What this patent protects
The invention relates to new thiohydantoin derivatives with pharmacological properties related to those of natural prostaglandins, intermediates therein, compositions containing the said derivatives, and their use in medicine. In particular, certain compounds have been found to b…
USPTO Abstract
The invention relates to new thiohydantoin derivatives with pharmacological properties related to those of natural prostaglandins, intermediates therein, compositions containing the said derivatives, and their use in medicine. In particular, certain compounds have been found to be potent mimetics of the anti-platelet aggregatory properties of prostaglandin E1.
Drugs covered by this patent
- Erleada (apalutamide) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.